New research shows that the proposed vaccine based on vaccinia virus (VACV) will generate a robust immune response to the monkeypox virus observed in the current outbreak (MPXV-2022).
Since the first discovery of the new virus in early May 2022, more than 52,000 cases have been confirmed in more than 90 countries and regions, Including Hong Kong, as the city recorded its first imported case on Monday.
The study was co-led by Professor Matthew McKay from the University of Melbourne and Professor Ahmed Abdul Quadeer, Research Associate, Hong Kong University of Science and Technology (HKUST) Professor, published in the international journalViruses
Several weeks after the emergence of the new strain, the team performed genomic studies to determine whether the genetic mutation observed in MPXV-2022 might affect vaccine-induced Immune response to monkeypox.
“In the past, specific VACV-based vaccines have demonstrated high efficacy against monkeypox virus and are considered important epidemic control measures,” said Professor McKay, who is also an adjunct professor at the Hong Kong University of Science and Technology.
“However, given that this is a novel monkeypox virus, we still lack information about the human immune response elicited by the VACV vaccine How will MPXV-2022 be identified and provide scientific data to prevent disease.”
Using genomic and immunological data, research team evaluates The genetic similarities and differences between VACV and MPXV-2022, especially in the regions targeted by intraprotein vaccine-induced neutralizing antibodies or T cells, were investigated.
“While we identified a small number of distinct mutations in MPXV-2022, our study more broadly showed that VACV and MPXV-2022 has a high degree of genetic similarity in regions targeted by the immune system through vaccination,” explained Professor McKay.
Prof. Quadeer said the findings were reassuring.
“Based on our analysis, we expect that VACV-based vaccines will continue to do well in identifying and responding to MPXV-2022 work, like the monkeypox virus in the past,” Professor Quadeer said.
“Our data further support the use of a globally recommended vaccine against MPXV-2022.”
The World Health Organization recommends primary preventive vaccination against the novel monkeypox virus, also known as pre-exposure prophylaxis, for individuals at high risk of exposure. In Hong Kong, the first vaccines are expected to arrive within this month.
“Combining both sequencing and immunological data provides evidence to predict robust immune responses, and clinical studies are needed to identify these vaccines The exact efficacy of MPXV-2022,” concluded Prof. McKay.
Further information: Syed Faraz Ahmed et al. Vaccine based on vaccinia virus expected to cause high crossover to monkeypox in 2022 Virus Virus (2022) Reactive Immunity. DOI: 10.3390/v14091960
Citation : Vaccine expected to induce strong immune response against 2022 monkeypox virus, study shows (September 9, 2022) in 2022 Retrieved September 21, 2022 from https://medicalxpress.com/news/2022-09-vaccine-strong-immune-responses-monkeypox. html
This document is protected by copyright. Except for any fair dealing for private study or research purposes, no part may be reproduced without written permission. The content is for reference only.